Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vulnerabilities of <i>PTEN</i> – <i>TP53</i> -Deficient Prostate Cancers to Compound PARP–PI3K Inhibition

28 May 2014

Abstract excerpt

UNLABELLED: Prostate cancer is the most prevalent cancer in males, and treatment options are limited for advanced forms of the disease. Loss of the PTEN and TP53 tumor suppressor genes is commonly observed in prostate cancer, whereas their compound loss is often observed in advanced prostate cancer. Here, we show that PARP inhibition triggers a p53-dependent cellular senescence in a PTEN-deficient setting in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to PARP inhibition in cancer therapy
Share to PI3K/AKT/mTOR signaling in cancer
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24866151
DOI: 10.1158/2159-8290.cd-13-0230

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vulnerabilities of <i>PTEN</i> – <i>TP53</i> -Deficient Prostate Cancers to Compound PARP–PI3K InhibitionPMID 24866151Read ↗

Biobank of genetically defined murine prostate cancer tumoroids uncovers oncogenic pathways and drug vulnerabilities driven by PTEN-lossSemantic proximity Read ↗

A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesisSemantic proximity Read ↗

The PTEN Conundrum: How to Target PTEN-Deficient Prostate CancerSemantic proximity Read ↗

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.Semantic proximity Read ↗

Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancerSemantic proximity Read ↗

Olaparib-Induced Senescence Is Bypassed through G2–M Checkpoint Override in Olaparib-Resistant Prostate CancerSemantic proximity Read ↗

<i>Pten</i> Deficiency Activates Distinct Downstream Signaling Pathways in a Tissue-Specific MannerSemantic proximity Read ↗

DNA Damage- But Not Enzalutamide-Induced Senescence in Prostate Cancer Promotes Senolytic Bcl-xL Inhibitor SensitivitySemantic proximity Read ↗

PTEN deletion in luminal cells of mature prostate induces replication stress and senescence in vivo.Semantic proximity Read ↗

Molecular Characterization of PARP Inhibitor Response Reveals Co-Targeting Strategies in Advanced Prostate CancerSemantic proximity Read ↗

Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication StressSemantic proximity Read ↗

<i>Pten</i> Inactivation and the Emergence of Androgen-Independent Prostate CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.